Impact of COVID-19 on the Relapse and Reawakening of Dormant Tumor Cells in Breast Cancer

Abstract

Worldwide, the study shows that breast cancer is one of the major cancer responsible for women death. All the effective therapies – immune-modulator therapy, chemo-radiation and cell targeted therapies can worsen the body immune system which majorly affects the lungs and these women with weak immune system and bronchi problems are more susceptible to major complications if they are exposed to COVID-19. In start of pandemic, it was difficult for healthcare system to manage the surgeries, scans and therapies of cancer patients without let them exposed to SARCoV-2, leads to delay in their treatment which can even more worsen condition for the patient. SARCoV-2 triggers the IL-6 release by the formation of neutrophil extracellular trap which can increase the complications in the breast cancer patient as well as it can also reactivate the relapsed dormant breast cancer cells. So, after seeing the condition of patients doctors decided that they can treat the patients by taking all measuring safety precautions during the admission to the hospital and found Anti-IL-6 receptor (tocilizumab) neutrophils inhibitor (alvestat) and JAK1/JAK2 inhibitors (baricitinib) effective and vaccines are also available in international market considering them safe and efficient for patient with breast cancer history or maybe undergoing in treatment.